Isconova gets $5.2M for vaccine work

Sweden's Isconova has secured financing of 30 million Swedish kronor ($5.2 million) from InnovationsKapital for its work in vaccine adjuvant technology. Isconova release

Suggested Articles

VBL got the green light after the committee looked at unblinded overall survival data for the second pre-planned interim analysis.

Eleusis researchers discovered that structural characteristics of the 2C-H class of psychedelics help to control asthma without behavioral effects.

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.